in recognition of the growing importance of good governance to all canadian institutions, the canadian foundation for governance research is offering annual bertram scholarships of $15,000 each to phd 世界杯2022赛程表淘汰赛 registered at canadian universities.  the scholarship will support the work of 世界杯2022赛程表淘汰赛 who are conducting research into organisational governance as part of their doctoral research project. 

to qualify for the scholarship, the doctoral research project should focus on a topic directly related to organizational governance, including for example:

• the importance of effective boards in enabling good decision-making and improving the functioning of canadian institutions;
• governance issues of interest to canadian boards of public, private, government-agency and not-for-profit organizations;
• the role of corporate governance in enabling positive societal impacts;
• governance best practices through the canadian perspective.

the following are examples of relevant topics, although by no means an exhaustive list:

• board’s role during black swan events (e.g. pandemic, financial distress)
• diversity beyond gender
• sustainability
• oversight of corporate culture
• cybersecurity/ it governance/data governance/privacy
• the board’s role in innovation
• board understanding of political risk
• board’s role in public policy

for full details on the bertram scholarship, visit the cfgr website. the deadline for application is may 28, 2020.

the fy20 defense appropriations act provides funding to the department of defense peer reviewed medical research program (prmrp) to support to support medical research projects of clear scientific merit and direct relevance to military health.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy20 prmrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

the vision and mission of the prmrp is improve the health, care, and well-being of all military service members, veterans, and beneficiaries by encouraging, identifying, selecting, and managing medical research projects of clear scientific merit and direct relevance to military health.

congressionally directed topic areas:  all applications submitted to the prmrp must address at least one of the fy20 prmrp congressionally directed topic areas.  the fy20 prmrp topic areas are as follows:

• arthritis
• burn pit exposure
• chronic migraine and post-traumatic headache
• congenital heart disease
• constrictive bronchiolitis
• diabetes
• dystonia
• eating disorders
• emerging viral diseases
• endometriosis
• epidermolysis bullosa
• familial hypercholesterolemia
• fibrous dysplasia
• focal segmental glomerulosclerosis
• food allergies
• fragile x
• frontotemporal degeneration
• guillain-barré syndromemorrhage control
• hepatitis b
• hydrocephalus
• immunomonitoring of intestinal transplants
• inflammatory bowel diseases
• interstitial cystitis
• metals toxicology
• mitochondrial disease
• musculoskeletal health
• myalgic encephalomyelitis/chronic fatigue syndrome
• myotonic dystrophy
• nutrition optimization
• pancreatitis
• pathogen-inactivated blood products
• plant-based vaccines
• polycystic kidney disease
• pressure ulcers
• pulmonary fibrosis
• resilience training
• respiratory health
• rheumatoid arthritis
• sleep disorders and restriction
• spinal muscular atrophy
• sustained release drug delivery
• vascular malformations
• women’s heart disease

https://cdmrp.army.mil/funding/prmrp

clinical trial award (for emerging viral diseases and respiratory health) – letter of intent due june 8, 2020

assistant professor level or above (or equivalent)

• supports the rapid implementation of clinical trials of novel interventions with the potential to have a significant impact on patient care in the topic areas of emerging viral disease and/or respiratory health.
• applications must address at least one of the focus area published in the program announcement.
• proposed projects may range from small proof-of-concept trials through large-scale, definitive trials.
• ind or ide applications to the fda, if needed, should be submitted to the fda before the prmrp application submission deadline.
• funding limit for clinical trial not defined; requested funding must be appropriate for the scope of work proposed.
• maximum period of performance is 4 years.

investigator-initiated research award (for emerging viral diseases and respiratory health) – letter of intent is due may 28, 2020

assistant professor level or above (or equivalent)

• supports research that will make an original and important contribution to the field of research and/or patient care in the topic areas of emerging viral diseases and/or respiratory health.
• applications must address at least one of the focus areas published in the program announcement.
• partnering pi options available.
• clinical trials will not be funded.
• maximum funding of $1.6 million for direct costs (plus indirect costs); $2.0 million for direct costs (plus indirect costs) for applications including a partnering pi option
• maximum period of performance is 4 years

technology/therapeutic development award (for emerging viral diseases and respiratory health) – letter of intent due may 28, 2020

assistant professor level or above (or equivalent)

• supports the translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, or quality of life in the topic areas of emerging viral diseases and/or respiratory health.
• applications must address at least one of the focus areas published in the program announcement.
• product-oriented (e.g., device, drug, clinical guidelines).  the product(s) to be developed may be a tangible item, such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product.
• clinical trials will not be funded.
• maximum funding of $4.0 million for direct costs (plus indirect costs)
• maximum period of performance is 4 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the prmrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact: 

cdmrp help desk
301-682-5507
help@ebrap.org

the fy20 defense appropriations act provides funding to the department of defense peer reviewed medical research program (prmrp) to support to support medical research projects of clear scientific merit and direct relevance to military health.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy20 prmrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

the vision and mission of the prmrp is improve the health, care, and well-being of all military service members, veterans, and beneficiaries by encouraging, identifying, selecting, and managing medical research projects of clear scientific merit and direct relevance to military health.

congressionally directed topic areas:  all applications submitted to the prmrp must address at least one of the fy20 prmrp congressionally directed topic areas.  the fy20 prmrp topic areas are as follows:

• arthritis
• burn pit exposure
• chronic migraine and post-traumatic headache
• congenital heart disease
• constrictive bronchiolitis
• diabetes
• dystonia
• eating disorders
• emerging viral diseases
• endometriosis
• epidermolysis bullosa
• familial hypercholesterolemia
• fibrous dysplasia
• focal segmental glomerulosclerosis
• food allergies
• fragile x
• frontotemporal degeneration
• guillain-barré syndromemorrhage control
• hepatitis b
• hydrocephalus
• immunomonitoring of intestinal transplants
• inflammatory bowel diseases
• interstitial cystitis
• metals toxicology
• mitochondrial disease
• musculoskeletal health
• myalgic encephalomyelitis/chronic fatigue syndrome
• myotonic dystrophy
• nutrition optimization
• pancreatitis
• pathogen-inactivated blood products
• plant-based vaccines
• polycystic kidney disease
• pressure ulcers
• pulmonary fibrosis
• resilience training
• respiratory health
• rheumatoid arthritis
• sleep disorders and restriction
• spinal muscular atrophy
• sustained release drug delivery
• vascular malformations
• women’s heart disease

https://cdmrp.army.mil/funding/prmrp

clinical trial award – letter of intent due july 29, 2020

assistant professor level or above (or equivalent)

new for fy20:  optional planning phase available.  the planning phase will provide support to prepare and submit an ind/ide application to the fda; fda/regulatory approval to proceed is required prior to exercising option for clinical trial.

planning phase (optional):

maximum of $500,000 for direct costs (plus indirect costs)

maximum period of performance is 18 months

clinical trial:

no maximum funding limit; requested funding must be appropriate for the scope of work proposed.

maximum period of performance is 4 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the prmrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact: 

cdmrp help desk
301-682-5507

the fy20 defense appropriations act provides funding to the department of defense prostate cancer research program (pcrp) to support innovative, high-impact prostate cancer research.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy20 pcrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

the mission of the fy20 pcrp is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of service members, veterans, and all the men and their families who are experiencing the impact of the disease.  within this context, the pcrp is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care, with an emphasis on investing in research that will benefit patients diagnosed with lethal prostate cancer or improve quality of life for men diagnosed with this disease.  all applications are required to address one or more of the following fy20 pcrp overarching challenges: 

• improve the quality of life for survivors of prostate cancer
• develop treatments that improve outcomes for men with lethal prostate cancer

applications must be directly relevant to lethal prostate cancer, which includes patients with metastatic disease; treatment-resistant disease; oligo-metastases; neuroendocrine disease; high-risk localized or locoregional disease, etc.

• reduce lethal prostate cancer in people of african descent, veterans, and high-risk or underserved populations

high-risk populations include, but are not limited to, people of african descent (including caribbean americans), genetically predisposed populations, service members, and veterans.  underserved populations include, but are not limited to, men with limited access to clinical care and resources (in both rural and urban settings), and sexual and/or gender minorities with, or at risk for, prostate cancer.

• define the biology of lethal prostate cancer to reduce death

applications must be directly relevant to lethal prostate cancer, which includes patients with metastatic disease; treatment-resistant disease; oligo-metastases; neuroendocrine disease; high-risk localized or locoregional disease; etc.  applications should not focus on topics such as differentiation between low risk and intermediate risk prostate cancer.

https://cdmrp.army.mil/funding/pcrp

idea development award – letter of intent due august 27, 2020

established investigators:  independent investigators at all levels

or

new investigators:  investigators that meet the following criteria at the application submission deadline date:

• have the freedom to pursue individual aims without formal mentorship
• have not previously received a pcrp idea development award and/or health disparity research award
• have either completed at least 3 years of postdoctoral training or fellowship or are within 10 years after completion of terminal degree (excluding residency or family leave)
• supports new ideas that represent innovative, high-risk/high-gain approaches to prostate cancer research and have the potential to make an important contribution to one or more of the fy20 pcrp overarching challenges.

• emphasis is equally placed on innovation and impact.
• preliminary data are encouraged, but not required.
• clinical trials are not allowed.
• each pi may submit only one application.

new investigator option supports applicants early in their faculty appointments or in the process of developing independent research careers.

established investigators:

• maximum funding of $750,000 for direct costs (plus indirect costs).

new investigators:

• maximum funding of $600,000 for direct costs (plus indirect costs).
• maximum period of performance is 3 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the pcrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507

the fy20 defense appropriations act provides funding to the department of defense prostate cancer research program (pcrp) to support innovative, high-impact prostate cancer research.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy20 pcrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

the mission of the fy20 pcrp is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of service members, veterans, and all the men and their families who are experiencing the impact of the disease.  within this context, the pcrp is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care, with an emphasis on investing in research that will benefit patients diagnosed with lethal prostate cancer or improve quality of life for men diagnosed with this disease.  all applications are required to address one or more of the following fy20 pcrp overarching challenges: 

• improve the quality of life for survivors of prostate cancer
• develop treatments that improve outcomes for men with lethal prostate cancer

applications must be directly relevant to lethal prostate cancer, which includes patients with metastatic disease; treatment-resistant disease; oligo-metastases; neuroendocrine disease; high-risk localized or locoregional disease, etc.

• reduce lethal prostate cancer in people of african descent, veterans, and high-risk or underserved populations

high-risk populations include, but are not limited to, people of african descent (including caribbean americans), genetically predisposed populations, service members, and veterans.  underserved populations include, but are not limited to, men with limited access to clinical care and resources (in both rural and urban settings), and sexual and/or gender minorities with, or at risk for, prostate cancer.

• define the biology of lethal prostate cancer to reduce death

applications must be directly relevant to lethal prostate cancer, which includes patients with metastatic disease; treatment-resistant disease; oligo-metastases; neuroendocrine disease; high-risk localized or locoregional disease; etc.  applications should not focus on topics such as differentiation between low risk and intermediate risk prostate cancer.

health disparity research award – letter of intent due june 25, 220

established investigators:  independent investigators at all levels

or

new investigators:  investigators that meet the following criteria at the application submission deadline date:

• have the freedom to pursue individual aims without formal mentorship
• have not previously received a pcrp health disparity research award and/or idea development award
• have either completed at least 3 years of postdoctoral training or fellowship or are within 10 years after completion of terminal degree (excluding residency or family leave)
• supports research ideas that have the potential to make an important contribution to reducing and ultimately eliminating disparities in prostate cancer incidence, morbidity, and mortality. 
• proposed projects must address one of the following health disparity focus areas: (1) access to healthcare, (2) social and cultural factors, (3) environmental factors, or (4) biological and genetic contributors.
• proposed projects may include basic, translational, population science, or clinical research, including clinical trials.
• primary emphasis will be placed on the potential impact of the proposed work.
• preliminary data are encouraged, but not required.

new investigator option supports applicants early in their faculty appointments or in the process of developing independent research careers.

established investigators:

• maximum funding of $750,000 for direct costs (plus indirect costs).

new investigators:

• maximum funding of $600,000 for direct costs (plus indirect costs).
• maximum period of performance is 3 years

translational science award – letter of intent due june 25, 2020

modified for fy20

independent investigators at all levels

• supports advanced translational research that will foster transformation of promising ideas in prostate cancer into clinical applications.
• supports a broad range of translational studies such as:

o  translation of results from animal studies to applications with human samples/cohorts

o  late-stage preclinical work leading to/preparing for a clinical trial, e.g., investigational new drug (ind) application submission

o  correlative studies that are associated with an open/ongoing or completed clinical trial

o  projects that develop endpoints for clinical trials

• preliminary data to support the feasibility of the research hypotheses and research approaches are required.  the inclusion of additional preliminary data to support the clinical relevance of the idea is strongly encouraged.
• clinical trials are not allowed.

new partnering pi option: allows two pis, termed initiating and partnering pis, to collaborate on a single application.  collaborations between basic science and clinical researchers are highly encouraged.

• maximum funding of $1,000,000 for direct costs (plus indirect costs).
• maximum period of performance is 3 years.

clinical trial award – letter of intent due to june 25, 2020

independent investigators at all levels

• supports hypothesis-based, early-phase clinical trials (e.g., phase 0, phase i, pilot phase ii) to test interventions that will have a major impact on one or more of the fy20 pcrp overarching challenges.
• interventions may include drugs, devices, biologics, targeted radionuclides, surgical procedures, behavior modifications, or other types.
• investigational new drug (ind) or investigational device exemption approvals, if applicable, must be in place by the time of application submission.
• letter of support to demonstrate proof of possession of sufficient drug supply to conduct study must be provided (if appropriate).
• clinical trials are expected to be initiated within 12 months of the award date.
• maximum funding of $2,000,000 for direct costs (plus indirect costs).
• maximum period of performance is 4 years.

population science and outcomes research award – letter of intent due june 25, 2020

new for fy20

independent investigators at all levels

• supports population-focused studies that will, if successful, identify and understand predictors of lethal prostate cancer or survivorship within the context of the fy20 pcrp overarching challenges.
• examples of appropriate research approaches include:

o  retrospective data analysis of patient databases or biospecimens

o  prospective observations, analyses, or sample collection from a patient population

o  case-control, cohort, or other population science study designs

• ·      clinical trials are not allowed.
• research ideas may include, but are not limited to, biomarkers for lethal disease; genetics/genomics; therapy and predictors of response or resistance; survivorship; and health disparity.
• requires demonstration of sufficient sample size to address the study objectives, a robust statistical plan, and strong biostatistical expertise in the study team.
• presentation of preliminary data to support the study of rationale and/or feasibility is strongly encouraged, but not required.
  • maximum funding of $1,000,000 for direct costs (plus indirect costs).
  • maximum period of performance is 3 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the pcrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

global affairs canada, in collaboration with the social sciences and humanities research council (sshrc), is pleased to announce the fifth edition of the international policy ideas challenge.  the objective of the program is to draw on the network of talented canadian graduate 世界杯2022赛程表淘汰赛 , post-doctoral fellows, and early-career civil society researchers to identify concrete, innovative solutions to emerging international policy challenges faced by canada.

the program offers applicants a chance to test their skills at translating academic expertise into policy language and insights. applicants are invited to submit brief proposals. ten winners will be given several months to consult with global affairs canada “client” divisions and further develop their proposals into longer policy briefs, which will then be presented to government of canada officials in a day-long ideas symposium, hosted by global affairs canada in ottawa in 2020.

daad (germany) - upcoming deadlines

the german academic exchange service (deutscher akademischer austauschdienst) is currently accepting applications for its short-term research mobility grant programs to german universities and research institutes. there are two application periods per year (may and october deadlines).  for information or assistance, please contact jill sherman, intl.research@lakeheadu.ca. please contact me as soon as possible if you plan to apply.

for phd 世界杯2022赛程表淘汰赛 / post-doc fellows – short-term research grants

the short-term research grant program provides funding for a research project at a recognized institution of higher education or a non-university research institute in germany, to be carried out in coordination with an academic advisor in germany. 

application deadline:  may 1, 2020

grant period:  october 1, 2020 -april 30, 2021

duration: 1-6 months

eligibility: canadian citizens/permanent residents, foreign 世界杯2022赛程表淘汰赛 who have been in canada for at least one year.  phd 世界杯2022赛程表淘汰赛 should be no more than 3 years past abd status. post-docs should be no more than 4 years after completing the phd. all academic disciplines are eligible.

award:  monthly stipend (€850 for graduate 世界杯2022赛程表淘汰赛 , €1,200 for post-docs), insurance, travel allowance.

aad (germany) - upcoming deadlines

the german academic exchange service (deutscher akademischer austauschdienst) is currently accepting applications for its short-term research mobility grant programs to german universities and research institutes. there are two application periods per year (may and october deadlines).  for information or assistance, please contact jill sherman, intl.research@lakeheadu.ca. please contact me as soon as possible if you plan to apply.

1. for faculty – research stays

the faculty research stay program provides funding for short-term research stays at recognized institutions of higher education or non-university research institutes in germany. awards are for research and working projects only.

application deadline:  may 15, 2020

project period:  october 1, 2020 -april 30, 2021

duration: 1-3 months

eligibility:  canadian citizens/permanent residents with full-time employment in research or teaching for at least 2 years after completion of the phd.  all academic disciplines are eligible.

award: monthly stipend (€2,000/month for assistant professors and lecturers, €2,150/month for tenured professors), and a travel allowance.

in 2020/21, meopar expects to offer up to three postdoctoral fellowship awards of $20,000. the purpose of these awards is to bring new postdoctoral fellows into the network to connect them with meopar-funded researchers and hqp.

proposed research activities that would be supported by an award must address meopar’s organizational objective (to connect partners, resources and expertise to prepare for risks and take advantage of opportunities in the changing marine environment), and must be linked to one of meopar’s four challenge areas: ocean observation; forecasting/projection; coastal resilience; and marine operations/transportation. refer to meopar’s strategic plan for more information.

awards will supplement existing funding support awarded to promising new scholars. to be considered for a meopar postdoctoral fellowship award, funding applicants must:

• receive a base level of financial support ($45,000) from additional sources: home department, supervisor research grants, and/or through government and agency scholarships or awards;
• demonstrate support from their supervisor for their work and their proposed use of the award funds;
• participate full‐time in their respective program at a canadian post-secondary institution that is eligible for tri-council funding; and
• engage in research aligned with the strategic plan of meopar.

application instructions and a frequently asked questions (faq) document are available on meopar's website.

the deadline to apply is 26 june 2020. questions about the award may be directed to laura avery.